Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEY-507 formulations versus Xyrem pharmacokinetic crossover study in healthy adults
NL-OMON43111Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of KEY-507-A, KEY-507-G, KEY-507-C, KEY-507-D and sodium oxybate in narcolepsy (5 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Relative bioavailability and bioequivalence. Started May 2016; status: active, not recruiting.
02
Drugs
KEY-507-AKEY-507-GKEY-507-CKEY-507-Dsodium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON43111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43111.